Lauren Hendricks
Family · Raleigh, NCNPI 1538598461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 952 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 952 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Lilly USA, LLC$2K
- Abbott$2K
- Amgen$1K
- Corcept Therapeutics$1K
- Mannkind Corporation$644
- plus $8K from 53 others
What the payments were for
- Food & beverage$16,906100%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$414
- TEPEZZA$237
- Korlym$236
- TWIIST$202
- GVOKE HYPOPEN$122
- MOUNJARO$113
- Wegovy$112
- Ozempic$109
How this compares
$16,951 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RecorlevLevoketoconazole | 12 | $749,280 |
| KorlymMifepristone | 12 | $518,112 |
| OzempicSemaglutide | 160 | $292,185 |
| MounjaroTirzepatide | 111 | $147,325 |
| JardianceEmpagliflozin | 75 | $94,786 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $88,675 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $74,874 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 26 | $42,852 |
| TrulicityDulaglutide | 23 | $31,557 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $30,317 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $23,847 |
| ProliaDenosumab | 13 | $22,461 |
| TradjentaLinagliptin | 18 | $20,937 |
| Repatha SureclickEvolocumab | 19 | $20,074 |
| FiaspInsulin Aspart (Niacinamide) | 16 | $19,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Xeris Pharmaceuticals, Inc.Recorlev | $470 | $749,28012 claims |
| Corcept TherapeuticsKorlym | $1,052 | $518,11212 claims |
| Novo NordiskOzempic, Fiasp, Novolog, Rybelsus | $2,545 | $342,690230 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $2,019 | $193,466181 claims |
| Boehringer IngelheimJardiance, Tradjenta | $306 | $115,72393 claims |
| AmgenProlia | $1,159 | $22,46113 claims |
| AbbVieSynthroid, Armour Thyroid | $556 | $18,514171 claims |
| AstraZenecaFarxiga | $357 | $18,17311 claims |
| MerckJanuvia | $16 | $10,32515 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $190 | $4,862383 claims |
| PfizerLevoxyl | $52 | $1,43618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Raleigh
- Michele CerraRaleigh$332K
- Carrie PettitRaleigh$298K
- Jennifer GibbsRaleigh$216K
- Holly StarnesRaleigh$69K
- Harry LayRaleigh$63K
- Margaretann HouseRaleigh$16K
- Gretchen ReichmannRaleigh$13K
- Leslie ByrneFayetteville$482K
- Anne LakeArchdale$306K
- Nicole RothmanDurham$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.